A Map That Only Leads to the Sea
There’s an image early in John Green’s Everything is Tuberculosis that I haven’t been able to shake. It’s a map of Sierra Leone’s railway system, laid down during British colonial rule. The lines don’t connect towns to each other. They don’t link communities, don’t facilitate trade between neighbors, don’t help anyone get to a hospital or a school. Every single rail line runs from an inland diamond or mineral deposit straight down to a coastal port. That’s it. Resources out, nothing back. The whole country reduced to a drainage diagram.
I kept coming back to that map while reading this summary, because it functions as a kind of skeleton key for everything Green is doing in this book. Tuberculosis, in his telling, is not fundamentally a story about a bacterium. It’s a story about plumbing—about the channels of extraction and neglect that wealthy nations have built through poorer ones, and how disease floods those channels with a logic that is almost architectural. The bacteria are opportunists. The real infrastructure of death was laid by human hands.
What the Book Actually Is
Let me back up. Everything is Tuberculosis is Green’s pivot from fiction into narrative nonfiction, and it’s an ambitious one. He braids together two very different strands. The first is a sweeping epidemiological history of Mycobacterium tuberculosis—the organism that has killed, by Green’s account, over a billion people in the last two centuries. The second is the intimate, ground-level story of a boy named Henry Reider, a young Sierra Leonean fighting extensively drug-resistant TB inside the crumbling infrastructure of Lakka Government Hospital.
The core argument, stripped to its studs: tuberculosis has been completely curable since the 1950s. It kills roughly 1.25 million people every year anyway. The reason it keeps killing is not biological mystery—it’s systemic cruelty. Colonial legacies, pharmaceutical monopolies, racist medical pseudoscience, and the cold arithmetic of cost-effectiveness analysis have all conspired to ensure that a solvable disease remains unsolved for anyone too poor to matter.
That’s a hell of a thesis. And for the most part, Green prosecutes it convincingly.
The Slowest Killer: Biology as Metaphor
The biological section of the book is genuinely compelling, partly because the organism itself is so strange. Most pathogens operate on speed—replicate fast, overwhelm the host, move on. Mycobacterium tuberculosis does the opposite. It divides about once a day, which in bacterial terms is almost geological. All that slow reproduction goes toward building an absurdly thick, waxy cell wall that the immune system’s white blood cells can’t easily breach. So the body does the next best thing: it walls the bacteria off, surrounding them with a calcified shell of dead tissue called a “tubercle.” The bacteria just sit there. Dormant. Feeding on dead cells. For decades, sometimes.
This is latent tuberculosis—a quarter of the world’s population is estimated to carry it. And here’s what’s striking: the shift from latent to active disease almost always maps onto social conditions. Malnutrition, HIV, overcrowded housing, stress. The immune system weakens, the tubercles crack open, the bacteria flood the lungs, and the patient begins coughing blood. Green puts it plainly: “M. tuberculosis is a near-perfect human predator in part because it moves very slowly… The body is slowly overwhelmed by infection (and the immune system’s resulting inflammation), eventually leading to death.”
Green anchors this biological primer in the 1882 work of Robert Koch, who isolated the rod-shaped bacteria from human tubercles, grew them in egg medium, and injected them into guinea pigs to prove that TB was infectious—not hereditary, not constitutional, not a mark of moral character. It’s the kind of discovery that should have changed everything. In a sense it did. But the social machinery around TB proved far more resistant to intervention than the bacillus itself.
I lingered on this section because the biology has a compelling irony to it. The very thing that makes TB so insidious—its patience, its willingness to wait inside a body for years—also makes it invisible in a way that serves powerful interests. A disease that kills quickly is frightening. A disease that kills slowly, quietly, mostly among the poor, is easy to forget about. And forgetting, as Green argues throughout the book, is itself a policy choice.
The Beautiful Death: Consumption and Its Discontents
Before Koch, tuberculosis went by other names—”consumption,” phthisis—and the cultural mythology wrapped around it was genuinely bizarre. Green traces how, during the Industrial Revolution, Northern European and American elites confronted a disease that was slaughtering people across every class. The response was not to fix the slums and factories. The response was to invent a story.
The story was spes phthisica, the “consumptive spirit.” Because TB killed slowly and left faces pale but flushed with fever, it was reimagined as a disease of sensitivity. Of beauty. Of artistic genius. The wasting body became evidence of a refining soul. Fashion trends emerged—extreme corsetry, belladonna drops to widen the eyes—that deliberately mimicked the look of a person dying of tuberculosis. The deaths of Keats, the Brontës, Chopin: these were not understood as public health catastrophes. They were understood as proof of transcendence.
Green contrasts this with the Japanese haiku poet Masaoka Shiki, who actually had TB, and who wrote about the claustrophobic horror of being a “phlegm-stuffed Buddha.” No romance there. Just suffocation.
What’s striking about the spes phthisica section—and I think it’s the most intellectually alive part of the whole book—is how cleanly Green draws the line from romanticization to dehumanization. He writes: “Imagining someone as more than human does much the same work as imagining them as less than human: Either way, the ill are treated as fundamentally other because the social order is frightened by what their frailty reveals about everyone else’s.” That sentence does a lot of work. It collapses the distance between the Victorian poet dying beautifully in a garret and the Sierra Leonean child dying anonymously in a ward, and it argues that both fates are manufactured by the same mechanism: a refusal to see the sick person as an ordinary human being who simply needs help.
The trouble is, Green could have pushed this further. The spes phthisica analysis is really an argument about how societies metabolize their own fear of death—how they create meaning-stories to contain the terror of mass mortality. There’s a version of this chapter that connects the Victorian consumption cult to our own era’s habit of turning cancer into a “battle” narrative, or of treating opioid deaths in Appalachia as a personal moral failing until fentanyl hit the suburbs. The mechanism is always the same: rewrite the catastrophe as something that happens to a certain kind of person for a certain kind of reason, and you’ve absolved the system. That’s a deeply rich vein, and Green taps it but doesn’t mine it. He moves on. I wanted him to stay.
Racialized Medicine and the Colonial Machine
Once Koch proved TB was infectious, the cultural narrative pivoted hard. If TB was a disease of filth and crowding, it could no longer be the romantic affliction of the civilized elite. It became, instead, a weapon aimed downward. Physicians began pushing the pseudoscience of “racial susceptibility”—the claim that Black Americans, Indigenous populations, and colonized peoples were genetically predisposed to TB because of smaller lungs or intellectual inferiority or whatever other garbage dressed itself up in medical language that particular decade.
Green is blunt about what this accomplished. It let white medical authorities ignore the actual drivers of the disease: Jim Crow segregation, the deliberate starvation of Indigenous children, the extractive brutality of colonial regimes. If TB was a genetic failing of the victim, then there was no obligation to provide clean housing or functioning healthcare.
The numbers he cites are staggering. In Canadian residential schools during the 1930s and 40s, the TB death rate among Indigenous children was 8,000 per 100,000. Eight percent of confined children dying annually. “People who are treated as less than fully human by the social order are more susceptible to tuberculosis,” Green writes. “But it’s not because of their moral codes or choices or genetics; it’s because they are treated as less than fully human by the social order.” The circularity is the point.
I’ll be honest—this section, while important and well-documented, felt compressed in a way that didn’t quite serve the material. The history of racialized TB science in the United States alone could fill its own book. Green gestures at it, but there’s a density to the colonial and Jim Crow connections that needed more room to breathe. He’s trying to cover four continents and two centuries of systematic cruelty in what feels like a chapter and a half, and the velocity sometimes flattens the specificity that would make individual stories land harder.
The Sanatorium and Its Children
The sanatorium section is short but devastating. Before antibiotics, the medical consensus was that rest, cold air, and total obedience could cure tuberculosis. Patients were isolated in massive facilities, stripped of agency, forbidden to speak or laugh or cry. The belief was that emotional disturbance could trigger lung hemorrhages. The system demanded what Green calls “moral hygiene”—survival reframed as a function of compliance. “In order to maximize the chance for a cure, one doctor wrote, ‘The smallest details of the patient’s life are controlled by the supervising physician and nothing of any importance is left to [the patient’s] judgment.’… Failure to give your life over to this total supervision was tantamount to suicide.”
Green tells the story of Gale Perkins, who contracted bone TB as a toddler and was confined to the Lakeville Sanatorium in Massachusetts for twelve years. At age four, she was put behind a screen for the crime of crying audibly. Solitary confinement. For a four-year-old. Her best friend Angie died there.
That image—a child punished for crying in a place where children go to die—is the kind of detail that burns through the page. And it does something structurally important for Green’s argument: it establishes a throughline from the sanatorium era to the modern DOTS program, showing how the paternalistic impulse to control the patient never really went away. It just changed uniforms.
DOTS, Paul Farmer, and Who Gets to Survive
This is where things get complicated. And where I have the most to say.
After the discovery of the RIPE antibiotic regimen—Rifampin, Isoniazid, Pyrazinamide, Ethambutol—TB became entirely curable. In the wealthy world, it more or less vanished as a mass killer. In the Global South, it kept raging. The WHO’s response was DOTS: Directly Observed Therapy, Short-course. The idea was that patients had to physically travel to a clinic every day and be watched swallowing their pills, because—and I’m paraphrasing the underlying assumption—poor people can’t be trusted to take their own medicine.
Green is scathing about DOTS, and he’s right to be. The program relied on cheap, inaccurate smear microscopy for diagnosis—the same basic technology from the nineteenth century, missing roughly half of active cases. It offered a one-size-fits-all treatment regimen. If a patient had Multidrug-Resistant TB, the system just fed them the failing first-line drugs again, which is a bit like treating a house fire by throwing the same wet towel at it that already failed to work. Treating MDR-TB with second-line drugs cost around $15,000, and global health economists declared it “not cost-effective.” Think about what that phrase actually means in practice. It means someone sat down with a spreadsheet, assigned a dollar value to a human life in the developing world, and concluded that saving it wasn’t worth the expense. Patients with resistant strains were abandoned to die, and the whole thing was wrapped in the bloodless language of fiscal responsibility. “When a program loses a large percentage of its patients, is this a compliance problem or a surveillance problem? Is it a patient’s fault when he or she cannot afford the food necessary to ward off the hunger brought on by the drugs?”
What gets me about the DOTS system is how neatly it mirrors the sanatorium logic from a century earlier. Different technology, same paternalism. The sanatorium said: lie still, don’t cry, obey the physician. DOTS said: show up every day, swallow your pills in front of us, and if the pills don’t work, that’s your problem. In both cases, the burden of failure is placed entirely on the patient. The system never has to account for its own inadequacy.
And then there’s Paul Farmer. Green profiles how Partners In Health, working in Peru in the late 1990s, ignored the WHO’s cost-effectiveness mandates entirely. PIH implemented community-based, individually tailored treatment for MDR-TB patients—complete with nutritional support, economic stipends, and the radical premise that a destitute Peruvian patient deserved the same standard of care as a patient in Boston. They achieved an 85 percent cure rate.
This is where I find the book most compelling and most frustrating simultaneously. Compelling because the Paul Farmer material is rock-solid—the data is clear, the moral argument is overwhelming, the proof of concept is right there. Frustrating because Green leans on it so heavily that it starts to function less as evidence and more as fable. The heroic NGO rides in, ignores the bureaucrats, saves the patients. It’s true. It happened. But it’s also a narrative shape that lets the reader off the hook. You nod along, you feel the righteous anger, and then—what? PIH saved hundreds of patients in Lima. The global TB pandemic kills 1.25 million people a year. The gap between those scales is where the hard questions live, and Green doesn’t spend enough time there.
He advocates for treating medicines as a public good and for public funding of drug development. Those are the right instincts. But the book skims over the geopolitical and legislative mechanics required to actually untether pharmaceutical R&D from the profit motive. The diagnosis is sharp. The prescription is vague.
The Patent Racket
The pharmaceutical section is infuriating, which I think is exactly what Green intended. There was a 46-year gap between the introduction of the RIPE drugs and the development of new TB compounds. Forty-six years. Because antibiotics for poor people are not profitable, and drugs for lifelong conditions in wealthy populations are.
When bedaquiline finally arrived—a genuinely effective new weapon against MDR-TB—Johnson & Johnson priced it out of reach. And then, as the primary patent neared expiration, J&J engaged in “patent evergreening”: filing secondary, frivolous patents on minor formulation tweaks to extend their monopoly and block generic production.
Green profiles two activists here. Shreya Tripathi sued the Indian government for the right to access bedaquiline—and won the case too late to save her own life. Phumeza Tisile survived MDR-TB but lost her hearing to toxic, outdated injectable drugs. She filed a legal challenge against J&J in India, got the secondary patents invalidated, and triggered a 60 percent drop in the global price of bedaquiline. Green’s line cuts clean: “This is a human-manufactured problem that needs a human solution. If medications were a public good, the burden of disease would drive the priorities of the industry and TB treatment would be varied and plentiful.”
The Cepheid/Danaher situation is equally galling. The GeneXpert rapid testing machine, whose underlying technology was developed with public funds, uses a razor-and-blades model: cheap machines, exorbitant single-use cartridges. A cartridge that costs under $5 to make was being sold for $14.90 to the world’s poorest countries. Sierra Leone’s entire healthcare budget is roughly $50 per person per year. A $25 diagnostic sequence doesn’t just strain the system—it collapses it. So nations fall back on 140-year-old smear microscopy that misses half of active cases.
I don’t have much to push back on here. The facts are the argument. Green presents them clearly, and they speak. If anything, this section is the most conventionally journalistic part of the book—less literary, more prosecutorial—and it works precisely because Green resists the urge to editorialize. The numbers do the editorializing for him. When your diagnostic cartridge costs less than $5 to manufacture and you’re charging $14.90 to countries where the entire annual healthcare budget per person is $50, there’s no spin that makes that look decent.
Henry, and the Question of Scale
The emotional backbone of the book is Henry Reider. His story threads through the larger history, and it’s the part that keeps you reading even when the policy sections get dense. Henry’s journey through Lakka Government Hospital—the failed diagnostics, the agonizing side effects of kanamycin, the social stigma, the slow unraveling of a child’s world—illustrates everything Green argues at the macro level, compressed into a single life.
Henry survived. Dr. Girum Tefera, leveraging global networks, assembled a tailored regimen of bedaquiline and delamanid. It worked. Green frames this as proof that “virtuous cycles” are possible, that treating a destitute patient with the same urgency and resources you’d give a patient in London or Boston can actually save a life. The phrase Green uses—a “preferential option for the poor”—comes loaded with theological weight, borrowed from liberation theology, and it’s doing real argumentative work here. It means that in a world of grotesque inequality, justice isn’t about treating everyone the same. It’s about directing the most resources toward those who have been most systematically deprived.
“Henry was sick not really because of Koch’s bacillus, but because of historical forces… His illness was a product of Sierra Leone’s centuries-long impoverishment, of a healthcare system hollowed out by colonization and war and Ebola, of a world that stopped caring about TB when it ceased to be a threat to the rich.”
And this is where the book is at its most powerful and also where I feel most conflicted. Henry’s story is beautiful. It’s also the story of one boy. Green knows this—he’s not naive. But the structure of the book, with Henry as its emotional anchor, risks creating the impression that the problem is solvable at the individual level, through heroism and advocacy and the right doctor making the right phone call. The systemic argument—that the whole architecture of global health needs dismantling and rebuilding—gets slightly blunted by the warmth of one particular happy ending.
Maybe that’s unfair. Maybe the point is precisely that you start with one person treated with full dignity, and you scale from there. Partners In Health started in one community in Haiti. But I keep thinking about the 1.25 million who die every year in the space between a proven concept and a functioning global system. Green connects this book to the intellectual lineage of Paul Farmer’s Infections and Inequalities, Tracy Kidder’s Mountains Beyond Mountains, and Vidya Krishnan’s Phantom Plague. It belongs in that company. What it shares with those books—and what it doesn’t quite escape—is a tendency to let moral clarity substitute for structural strategy.
What Stays With You
I finished the summary with a strange feeling. Not hope exactly, and not despair. Something more like vertigo. The book is very good at stripping away the comfortable fictions—that TB is a thing of the past, that modern medicine is distributed according to need, that cost-effectiveness analysis is a neutral tool. It’s less good at telling you what to do once those fictions are gone. And maybe that gap matters more than I initially thought, because the reader who feels the moral outrage but has no structural framework for action is a reader who will, eventually, move on to the next book. Green’s power as a writer—his celebrity, his massive platform, his ability to make the general public care about something they’d previously filed under “solved”—is precisely what makes the vagueness of his policy prescriptions feel like a missed opportunity. He has the audience. He has their attention. The question is whether moral urgency alone is enough to change anything, or whether it needs to be paired with something harder and more specific.
But maybe that’s the honest position. Maybe a book can only do one thing well, and what this book does well is force you to see. Green’s line about how “imagining someone as more than human does much the same work as imagining them as less than human” has been rattling around in my head for days. There’s something in that sentence about the fundamental dishonesty of how wealthy societies process suffering—always finding a way to make it about us, about our narratives, our categories, our comfort. The Victorian poet made consumption beautiful. The modern economist makes TB death “cost-ineffective to prevent.” Different stories, same function: permission not to act.
And that, finally, is what connects the spes phthisica mythology to the DOTS program to the patent evergreening to the railway map. They’re all stories told by the powerful to explain why the suffering of others is acceptable—natural, inevitable, even rational. Green’s best trick is showing you that none of these stories survive contact with a single real person. Henry Reider, coughing in a ward in Lakka. Gale Perkins, four years old, put behind a screen. Shreya Tripathi, winning her court case and dying anyway.
I keep going back to that railway map of Sierra Leone. Lines running only to the sea.
If you’d like to read the full book in EPUB or MOBI format, feel free to send me an email—I’d be happy to share a free copy with you. Please reach me at: thenovaleaf@gmail.com